Pancreatic Cancer Research

ResearcherOsaka City UniversityNo recent work listed

Masaichi Ohira

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3732-8053; OpenAlex author ID A5102135903. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper

Papers 10

  1. Establishment of a Liver Transplant Patient-derived Tumor Xenograft (PDX) Model Using Cryopreserved Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.14234↗
  2. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  3. [A Case of Male Breast Cancer Suspected of Breast Metastasis from Pancreatic Cancer]. Last author PMID 30692377↗
  4. Analysis of the origin of anaplastic pancreatic cancer and the mechanism of its dedifferentiation. Last author DOI 10.1002/jhbp.429↗
  5. Preoperative predictors for early recurrence of resectable pancreatic cancer. Last author DOI 10.1186/s12957-016-1078-z↗
  6. Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2. Co-author DOI 10.1186/s12885-016-2297-y↗
  7. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma. Co-author DOI 10.1186/1477-7819-12-360↗
  8. [A case of locally advanced pancreatic cancer with hepatic artery invasion treated with neoadjuvant chemoradiotherapy]. Co-author PMID 24393948↗
  9. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31821ad8d1↗
  10. HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Co-author DOI 10.1159/000333825↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryosuke Amano · 9 shared papers, 2011–2020 · strength 0.49
  2. Kenjiro Kimura · 8 shared papers, 2011–2020 · strength 0.46
  3. Sadaaki Yamazoe · 7 shared papers, 2011–2020 · strength 0.43
  4. Kosei Hirakawa · 8 shared papers, 2011–2018 · strength 0.39
  5. Kohei Nishio · 4 shared papers, 2014–2017 · strength 0.24
  6. Kotaro Miura · 3 shared papers, 2014–2017 · strength 0.16
  7. Masakazu Yashiro · 2 shared papers, 2016–2020 · strength 0.15
  8. Akihiro Murata · 3 shared papers, 2013–2016 · strength 0.12
  9. Hiroji Shinkawa · 1 shared paper, 2020 · strength 0.09
  10. Ryota Tanaka · 1 shared paper, 2020 · strength 0.09
  11. Shoji Kubo · 1 shared paper, 2020 · strength 0.09
  12. Koji Takada · 1 shared paper, 2018 · strength 0.07
  13. Shingo Asahara · 1 shared paper, 2019 · strength 0.07
  14. Masahiro Katsuda · 1 shared paper, 2019 · strength 0.07
  15. Hiroaki Nagano · 1 shared paper, 2019 · strength 0.07
  16. Kentaro Sudo · 1 shared paper, 2019 · strength 0.07
  17. Kenichi Hakamada · 1 shared paper, 2019 · strength 0.07
  18. Sohei Satoi · 1 shared paper, 2019 · strength 0.07
  19. Suguru Yamada · 1 shared paper, 2019 · strength 0.07
  20. Tatsuya Ioka · 1 shared paper, 2019 · strength 0.07
  21. Masayuki Furukawa · 1 shared paper, 2019 · strength 0.07
  22. Kazuo Hara · 1 shared paper, 2019 · strength 0.07
  23. Hiroki Yamaue · 1 shared paper, 2019 · strength 0.07
  24. Motoki Miyazawa · 1 shared paper, 2019 · strength 0.07
  25. Takahiro Akahori · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.